AstraZeneca says its COVID-19 vaccine could be around 90 per cent effective, and is potentially cheaper to make, easier to distribute and faster to scale-up than rival vaccine developments.
The British drugmaker said it will have as many as 200 million doses by the end of 2020 – around four times as many as US competitor Pfizer.
Seven hundred million doses could be ready globally as soon as the end of the first quarter of 2021.
The vaccine was 90 per cent effective in preventing COVID-19 when it was administered as a half dose followed by a full dose at least a month later, according to data from late-stage trials in Britain and Brazil. No serious safety events were confirmed, the company said.
Read more here.